The invention refers to an anti-oxMIF/anti-CD3 antibody comprising at least one binding site specifically recognizing oxMIF and one binding site specifically recognizing CD3, which is an IgG wherein a scFv is fused to only one of the two heavy IgG chains, an IgG wherein one Fab arm is replaced by a bispecific-T-cell-engager (BiTE), or an IgG wherein both Fab arms are replaced by scFvs with different binding specificities, and its use in the treatment of hyperproliferative diseases, specifically in the treatment of cancer.

The invention refers to an anti-oxMIF/anti-CD3 antibody comprising at least one binding site specifically recognizing oxMIF and one binding site specifically recognizing CD3, which is an IgG wherein a scFv is fused to only one of the two heavy IgG chains, an IgG wherein one Fab arm is replaced by a bispecific-T-cell-engager (BiTE), or an IgG wherein both Fab arms are replaced by scFvs with different binding specificities, and its use in the treatment of hyperproliferative diseases, specifically in the treatment of cancer.

The present invention is directed to use of kifunensine for increasing sialylation of a glycosylated polypeptide, wherein a cell that produces the glycosylated polypeptide is contacted with kifunensine. Also provided are related methods for increasing sialylation of a glycosylated polypeptide and producing a glycosylated polypeptide, as well as glycosylated polypeptides and pharmaceutical compositions comprising the same, and their use in medicine.

The present invention relates to compositions and methods for the treatment and prevention of thrombogenic-related diseases and disorders. The compositions may comprise antigen-binding fragments that prevent platelet activation by either blocking Fc.sub.γRIIa binding on platelets, neutrophils and monocytes, or neutralising platelet factor 4.

The present invention relates to compositions and methods for the treatment and prevention of thrombogenic-related diseases and disorders. The compositions may comprise antigen-binding fragments that prevent platelet activation by either blocking Fc.sub.γRIIa binding on platelets, neutrophils and monocytes, or neutralising platelet factor 4.

Disclosed herein are antibodies that specifically bind and inhibit the action of the IL-6 family member LIF that are useful in the treatment of cancer. Also disclosed herein are uses of said antibodies for the treatment of cancer.

The present invention relates to C-X-C motif chemokine ligand 10 (CXCL10) binding proteins and uses thereof in methods of detecting and/or diagnosing a condition in a subject, comprising determining a level of CXCL10 in the subject. Specific antibodies that bind to total CXCL10 (full-length, N-terminally truncated and citrullinated) and antibodies that bind active CXCL10 (full-length) were used to measure the level of total and active CXCL10 in samples from ovarian cancer patients. The calculated ratio of active to total CXCL10 was lower in patients with malignant condition when compared to patients with benign tumours or healthy individuals and is the basis of method of diagnosis of malignant conditions, monitoring tumour burden and disease progression.

The present invention relates to C-X-C motif chemokine ligand 10 (CXCL10) binding proteins and uses thereof in methods of detecting and/or diagnosing a condition in a subject, comprising determining a level of CXCL10 in the subject. Specific antibodies that bind to total CXCL10 (full-length, N-terminally truncated and citrullinated) and antibodies that bind active CXCL10 (full-length) were used to measure the level of total and active CXCL10 in samples from ovarian cancer patients. The calculated ratio of active to total CXCL10 was lower in patients with malignant condition when compared to patients with benign tumours or healthy individuals and is the basis of method of diagnosis of malignant conditions, monitoring tumour burden and disease progression.

The present disclosure relates to IL12 receptor agonists with improved therapeutic profiles.

Methods for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a treatment with a safe and effective amount of an anti-IL-12/IL-23p40 antibody or an anti-IL-23 antibody, e.g., informs on what patients to treat with the anti-IL-12/IL-23p40 antibody ustekinumab.